About Sun Pharma
Sun Pharmaceuticals Ltd. is India's largest (by market capitalization) and the world's 5th largest specialty generic pharmaceutical company. The company manufactures and sells high-quality, affordable medicines in over 150 countries across 6 continents.
As of 31st March 2015, Sun Pharmaceuticals Ltd. had an intellectual capital of 2,000+ scientists, and had invested over 7% of its annual revenues in R&D. The company has over 48 manufacturing facilities across the globe. 30 of their brands are among the top 300 pharma brands in India.
The company markets its pharmaceutical formulations as generics and branded generics in India and all major international markets. The therapeutic segments covered by the company's portfolio of 2000+ molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.
Sun Pharma's business is broadly categorized into four segments: Active Pharmaceutical Ingredients (API), International Branded Generics, Indian Branded Generics and US Generics.
They also make specialty APIs that include steroids, hormones, peptides and anti-cancers manufactured at 14 international standard manufacturing facilities around the world.
Over 72% of Sun Pharma sales are from overseas markets. The US is its single largest market, accounting for almost 60% of its turnover.
Sun Pharma at-a-glance*
FDA-USA, EMA-Europe, MHRA-UK, MCC-South Africa, TGA-Australia, ANVISA-Brazil, WHO-Geneva, BfArM-Germany, KFDA-Korea and PMDA-Japan
Turnover (year ended 31 March, 2015)
USD 4.5 billion
Market Share (India)
Distributors & Sales Reps (India)
History of Sun Pharma
Sun Pharmaceutical Industries Ltd. was incorporated in Kolkata in the year 1983. It commenced operations as a partnership firm by Dilip Shanghvi and his family, with 5 products to treat psychiatry ailments. Starting from two states (West Bengal and Bihar), it began to roll out national level sales within 2 years (by 1985). The company introduced cardiology products in 1987 followed by gastroenterology products in 1989.
Sun Pharma established the SPARC research center in 1993 to create a base of strong product and process development skills. In subsequent years, the company invested significantly in Research & Development of pharmaceutical formulations.
Listed on the main stock exchanges in India in 1994, Sun Pharma has grown to become the largest chronic prescription company in India today, and is a market leader (by prescription rank) in the following doctor categories, post Ranbaxy acquisition (as of June 2015):
- Consulting Physicians
- Chest Physicians
- 1983 - Starts operations in Kolkata with 5 psychiatry based products
- 1987 - Rolls out Marketing operations nationwide
- 1988 - Launches Monotrate and Angizem brands and with them the first few cardiology products
- 1989 - Introduces Gastroenterology products
- 1994 - Gets listed on the major stock exchanges in India after IPO
- 1995 - Starts production at the first API plant in Panoli
- 1996 - Acquires Knoll Pharma's API manufacturing unit located in Ahmednagar
- 1997 - Begins international acquisitions: acquires stake in Detroit-based Caraco Pharm Labs, buys equity stake in MJ Pharma and TDPL
- 1998 - Acquires a basket of brands from Natco Pharma and its new formulation plant begins operations at Silvassa
- 1999 - Achieves merger of Milmet Labs (Opthalmology) and Gujarat Lyka Organics (manufacturer of Cephalexin API)
- 2000 - Acquires Pradeep Drug Company
- 2001 - Builds a new formulation international standard plant in Dadra
- 2002 & 2003 - Ranked by Forbes Global as one of the best small 200 companies with a turnover of less than $500 million (2002 & 2003)
- 2004 - Acquires Phlox Pharma (Cephalosporin Actives manufacturer) and buys niche brands (gynecological Ortho-Est® estropipate, and anti-migraine Midrin®) from the San Diego, Women's First Healthcare
- 2005 - Buys out a manufacturing plant in Bryan, Ohio, USA, acquires the assets and intellectual property of Able Labs and takes over the business of ICN from Valeant Pharma in Hungary
- 2006 - Acquires Romanian Generics company Terapia
- 2007 - Completes demerger of innovative business with legal approvals which led to the formation of SPARC Ltd.
- 2008 - Acquires complete ownership of Chattem Chemicals, Inc., approved manufacturer of controlled substances in Tennessee, USA
- 2010 - Completes acquisition of a controlling stake in Taro Pharmaceutical Industries Ltd., a multinational generic manufacturer
- 2012 - Completes two more acquisitions in USA: Dusa Pharmaceuticals and generic business of URL Pharmaceuticals
- 2014 - Acquires 100% of Ranbaxy in an all-stock transaction
BOARD OF DIRECTORS
- Founder: Dilip Shanghvi
- Chairman: Israel Makov
- Managing Director Dilip Shanghvi
- Executive Directors Sudhir V. Valia, Sailesh T. Desai
- Non-Executive / Independent Directors: Hasmukh S. Shah, Keki M. Mistry, Ashwin Dani, S. Mohanchand Dadha, Rekha Sethi
Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Inc.